메뉴 건너뛰기




Volumn 43, Issue 6, 2013, Pages 616-628

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: Subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial

Author keywords

Axitinib; Clinical trial; Phase III; Renal cell carcinoma; Vascular endothelial growth factor receptors

Indexed keywords

AXITINIB; SORAFENIB;

EID: 84878628526     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt054     Document Type: Article
Times cited : (72)

References (51)
  • 2
    • 42649145828 scopus 로고    scopus 로고
    • Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
    • Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:19-205.
    • (2008) Cancer Treat Rev , vol.34 , pp. 19-205
    • Gupta, K.1    Miller, J.D.2    Li, J.Z.3    Russell, M.W.4    Charbonneau, C.5
  • 4
    • 84873928427 scopus 로고    scopus 로고
    • based on November 2010 SEER data submission. Bethesda, MD: National Cancer Institute (NCI),16 May 2012, date last accessed
    • Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR), 1975-2009, National Cancer Institute (based on November 2010 SEER data submission). Bethesda, MD: National Cancer Institute (NCI) 2010. http://seer.cancer.gov/csr/1975_2009_pops09 (16 May 2012, date last accessed).
    • (2010) SEER Cancer Statistics Review (CSR), 1975-2009, National Cancer Institute
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 5
    • 84878636874 scopus 로고    scopus 로고
    • American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society,(7 December 2011, date last accessed).
    • American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771. pdf (7 December 2011, date last accessed).
    • (2011)
  • 6
    • 77955493600 scopus 로고    scopus 로고
    • EAU guidelines on renal cell carcinoma: the 2010 update
    • Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
    • (2010) Eur Urol , vol.58 , pp. 398-406
    • Ljungberg, B.1    Cowan, N.C.2    Hanbury, D.C.3
  • 7
    • 69749124027 scopus 로고    scopus 로고
    • Guideline for management of the clinical T1 renal mass
    • Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-9.
    • (2009) J Urol , vol.182 , pp. 1271-1279
    • Campbell, S.C.1    Novick, A.C.2    Belldegrun, A.3
  • 9
    • 80755140681 scopus 로고    scopus 로고
    • Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    • Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011;47:2592-602.
    • (2011) Eur J Cancer , vol.47 , pp. 2592-2602
    • Tomita, Y.1    Uemura, H.2    Fujimoto, H.3
  • 11
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 12
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
    • (2009) J Clin Oncol , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 13
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 14
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    • Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 15
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    • Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3
  • 16
    • 77956048116 scopus 로고    scopus 로고
    • Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients
    • Ueda T, Imamura Y, Komaru A, et al. Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients. Int J Urol 2010;17:811-5.
    • (2010) Int J Urol , vol.17 , pp. 811-815
    • Ueda, T.1    Imamura, Y.2    Komaru, A.3
  • 17
    • 84856149515 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma
    • Suyama T, Ueda T, Fukasawa S, et al. Efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma. J Cancer Ther 2011;2:335-41.
    • (2011) J Cancer Ther , vol.2 , pp. 335-341
    • Suyama, T.1    Ueda, T.2    Fukasawa, S.3
  • 18
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 19
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 20
    • 58149337448 scopus 로고    scopus 로고
    • Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    • Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14: 7272-83.
    • (2008) Clin Cancer Res , vol.14 , pp. 7272-7283
    • Hu-Lowe, D.D.1    Zou, H.Y.2    Grazzini, M.L.3
  • 21
    • 44649151405 scopus 로고    scopus 로고
    • Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors
    • Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008;9: 658-71.
    • (2008) Curr Opin Investig Drugs , vol.9 , pp. 658-671
    • Choueiri, T.K.1
  • 22
    • 72449131348 scopus 로고    scopus 로고
    • Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
    • Kelly RJ, Rixe O. Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 2009;4: 297-305.
    • (2009) Target Oncol , vol.4 , pp. 297-305
    • Kelly, R.J.1    Rixe, O.2
  • 23
    • 77958043734 scopus 로고    scopus 로고
    • Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    • Goldstein R, Pickering L, Larkin J. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Rev Anticancer Ther 2010;10:1545-57.
    • (2010) Expert Rev Anticancer Ther , vol.10 , pp. 1545-1557
    • Goldstein, R.1    Pickering, L.2    Larkin, J.3
  • 24
    • 79959482485 scopus 로고    scopus 로고
    • Axitinib for the management of metastatic renal cell carcinoma
    • Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011;11:113-26.
    • (2011) Drugs R D , vol.11 , pp. 113-126
    • Escudier, B.1    Gore, M.2
  • 25
    • 35448934762 scopus 로고    scopus 로고
    • Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
    • Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84.
    • (2007) Lancet Oncol , vol.8 , pp. 975-984
    • Rixe, O.1    Bukowski, R.M.2    Michaelson, M.D.3
  • 26
    • 50649095801 scopus 로고    scopus 로고
    • Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    • Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
    • (2008) J Clin Oncol , vol.26 , pp. 4708-4713
    • Cohen, E.E.1    Rosen, L.S.2    Vokes, E.E.3
  • 27
    • 70349388719 scopus 로고    scopus 로고
    • Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    • Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
    • (2009) J Clin Oncol , vol.27 , pp. 4462-4468
    • Rini, B.I.1    Wilding, G.2    Hudes, G.3
  • 28
    • 68949127256 scopus 로고    scopus 로고
    • Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study
    • Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41.
    • (2009) J Clin Oncol , vol.27 , pp. 3836-3841
    • Schiller, J.H.1    Larson, T.2    Ou, S.H.3
  • 29
    • 82555173114 scopus 로고    scopus 로고
    • Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
    • Fruehauf JP, Lutzky J, McDermott DF, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9.
    • (2011) Clin Cancer Res , vol.17 , pp. 7462-7469
    • Fruehauf, J.P.1    Lutzky, J.2    McDermott, D.F.3
  • 30
    • 3142778420 scopus 로고    scopus 로고
    • Epidemiology of renal cell carcinoma
    • Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004;93:88-96.
    • (2004) Scand J Surg , vol.93 , pp. 88-96
    • Lindblad, P.1
  • 32
    • 34250867924 scopus 로고    scopus 로고
    • Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002
    • Marumo K, Kanayama H, Miyao N, et al. Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 2007;14:479-82.
    • (2007) Int J Urol , vol.14 , pp. 479-482
    • Marumo, K.1    Kanayama, H.2    Miyao, N.3
  • 33
    • 56749161670 scopus 로고    scopus 로고
    • Emerging ethnic differences in lung cancer therapy
    • Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62.
    • (2008) Br J Cancer , vol.99 , pp. 1757-1762
    • Sekine, I.1    Yamamoto, N.2    Nishio, K.3    Saijo, N.4
  • 34
    • 77957272015 scopus 로고    scopus 로고
    • Kidney Cancer Working Group report
    • Naito S, Tomita Y, Rha SY, et al. Kidney Cancer Working Group report. Jpn J Clin Oncol 2010;40(Suppl. 1):i51-6.
    • (2010) Jpn J Clin Oncol , vol.40 , Issue.SUPPL. 1
    • Naito, S.1    Tomita, Y.2    Rha, S.Y.3
  • 35
    • 84865473303 scopus 로고    scopus 로고
    • Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study
    • May 20,abstr 4503
    • Rini BI, Grünwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012;30, No. 15 (May 20 Suppl; abstr 4503).
    • (2012) J Clin Oncol , vol.30 , Issue.15 SUPPL.
    • Rini, B.I.1    Grünwald, V.2    Fishman, M.N.3
  • 36
    • 84878668259 scopus 로고    scopus 로고
    • Nexavarw (sorafenib) prescribing information.New Jersey Bayer Healthcare Pharmaceuticals Inc, 27 June 2012, date last accessed
    • Nexavarw (sorafenib) prescribing information. New Jersey Bayer Healthcare Pharmaceuticals Inc 2005 http://labeling.bayerhealthcare. com/html/products/pi/Nexavar_PI.pdf (27 June 2012, date last accessed).
    • (2005)
  • 37
    • 33745141600 scopus 로고    scopus 로고
    • Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
    • Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 2006;4:191-9.
    • (2006) J Support Oncol , vol.4 , pp. 191-199
    • Cella, D.1    Yount, S.2    Du, H.3
  • 38
    • 34447569323 scopus 로고    scopus 로고
    • Development and validation of a scale to measure disease-related symptoms of kidney cancer
    • Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007;10:285-93.
    • (2007) Value Health , vol.10 , pp. 285-293
    • Cella, D.1    Yount, S.2    Brucker, P.S.3
  • 39
    • 8944243553 scopus 로고    scopus 로고
    • Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system
    • Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 1996;5:309-20.
    • (1996) Qual Life Res , vol.5 , pp. 309-320
    • Bonomi, A.E.1    Cella, D.F.2    Hahn, E.A.3
  • 40
    • 18244368960 scopus 로고    scopus 로고
    • A comprehensive method for the translation and cross-cultural validation of health status questionnaires
    • Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 2005;28:212-32.
    • (2005) Eval Health Prof , vol.28 , pp. 212-232
    • Eremenco, S.L.1    Cella, D.2    Arnold, B.J.3
  • 41
    • 17144423549 scopus 로고    scopus 로고
    • Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation
    • Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8:94-104.
    • (2005) Value Health , vol.8 , pp. 94-104
    • Wild, D.1    Grove, A.2    Martin, M.3
  • 42
    • 84878640468 scopus 로고    scopus 로고
    • New York, NY: Pfizer Inc 2012,30 August 2012, date last accessed
    • Inlytaw (axitinib) tablets prescribing information. New York, NY: Pfizer Inc 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 (30 August 2012, date last accessed).
    • Inlytaw (axitinib) tablets prescribing information.
  • 43
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
    • Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 44
    • 72149129759 scopus 로고    scopus 로고
    • Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
    • Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-25.
    • (2010) Eur Urol , vol.57 , pp. 317-325
    • Naito, S.1    Yamamoto, N.2    Takayama, T.3
  • 45
    • 36249017922 scopus 로고    scopus 로고
    • Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    • Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 755-762
    • Akaza, H.1    Tsukamoto, T.2    Murai, M.3    Nakajima, K.4    Naito, S.5
  • 46
    • 84879321714 scopus 로고    scopus 로고
    • Axitinib vs Sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors
    • abstr 793PD
    • Motzer RJ, Escudier B, Tomczak P, et al. Axitinib vs Sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors. Ann Oncol 2012;23:ix262. (Suppl 9; abstr 793PD).
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 9
    • Motzer, R.J.1    Escudier, B.2    Tomczak, P.3
  • 47
    • 75549086120 scopus 로고    scopus 로고
    • Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
    • Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010;65:563-70.
    • (2010) Cancer Chemother Pharmacol , vol.65 , pp. 563-570
    • Pithavala, Y.K.1    Tortorici, M.2    Toh, M.3
  • 48
    • 77957269382 scopus 로고    scopus 로고
    • Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients
    • Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 2010;101:963-8.
    • (2010) Cancer Sci , vol.101 , pp. 963-968
    • Mukohara, T.1    Nakajima, H.2    Mukai, H.3
  • 49
    • 84864351085 scopus 로고    scopus 로고
    • Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
    • Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 2012;30:1055-64.
    • (2012) Invest New Drugs , vol.30 , pp. 1055-1064
    • Fujiwara, Y.1    Kiyota, N.2    Chayahara, N.3
  • 50
    • 84864287868 scopus 로고    scopus 로고
    • Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
    • Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68:645-55.
    • (2012) Eur J Clin Pharmacol , vol.68 , pp. 645-655
    • Brennan, M.1    Williams, J.A.2    Chen, Y.3    Tortorici, M.4    Pithavala, Y.5    Liu, Y.C.6
  • 51
    • 84856512778 scopus 로고    scopus 로고
    • A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG-013736, an anti-angiogenic agent
    • abstr PI-28
    • Garrett M, Houk BE, Myrand SP, Hee B, Mota J, Pithavala YK. A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG-013736, an anti-angiogenic agent. Clin Pharmacol Ther 2007;81:S21 (Suppl 1; abstr PI-28).
    • (2007) Clin Pharmacol Ther , vol.81 , Issue.SUPPL. 1
    • Garrett, M.1    Houk, B.E.2    Myrand, S.P.3    Hee, B.4    Mota, J.5    Pithavala, Y.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.